Unichem Labs Q1FY27 Consolidated Income at ₹632.62 Cr, Net Profit ₹41.47 Cr
Unichem Laboratories Limited reported Q1FY27 consolidated results with total income at ₹632.62 crore and net profit at ₹41.47 crore. Standalone profit after tax was ₹5.53 crore. The company also settled a Euro 19.55 million fine with the EU.
The financial results show a strong recovery and growth, which is positive for the company. However, the settlement of the EU fine, while resolving a past issue, does not represent new business growth.
The company has shown significant improvement in net profit for the quarter compared to the previous year and quarter, indicating positive financial performance. The settlement of the EU fine also removes a past liability.
Unichem Laboratories Limited has announced its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported a total income from operations of ₹632.62 crore for the quarter, an increase from ₹575.12 crore in the previous quarter and ₹526.60 crore in the corresponding quarter of the previous year.
The net profit after tax for the quarter stood at ₹41.47 crore, compared to ₹10.91 crore in the previous quarter and a loss of ₹10.47 crore in the same quarter last year. The total comprehensive income for the period was ₹38.41 crore.
The company also provided details regarding a settlement with the European Commission (EU) concerning a fine and interest totaling Euro 19.55 million. This was fully settled by the company on October 28, 2025, after adjusting previous payments. A provision for the fine of Euro 13.96 million was recognized in the year ended March 31, 2024, with the balance amount representing interest recorded under exceptional items in the year ended March 31, 2026.
The standalone financial results for the quarter ended June 30, 2026, showed a profit after tax of ₹5.53 crore, a significant improvement from a loss of ₹1.85 crore in the same quarter last year. Total income from operations for standalone results was ₹366.27 crore.
What to do with a filing like this
Unichem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Unichem Laboratories Limited. Read the original for the full detail.